FRTX Stock - Fresh Tracks Therapeutics, Inc.
Unlock GoAI Insights for FRTX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|
| Revenue | $8.01M | $6.94M | $404,000 | $1.82M | $7.92M |
| Gross Profit | $8.01M | $-7,100,000 | $-27,827,000 | $-9,394,000 | $-12,297,000 |
| Gross Margin | 100.0% | -102.3% | -6887.9% | -515.6% | -155.3% |
| Operating Income | $-6,360,000 | $-21,534,000 | $-40,244,000 | $-20,976,000 | $-24,468,000 |
| Net Income | $-5,694,000 | $-20,661,000 | $-39,521,000 | $-20,903,000 | $-25,945,000 |
| Net Margin | -71.1% | -297.6% | -9782.4% | -1147.3% | -327.7% |
| EPS | $-0.96 | $-7.36 | $-22.14 | $-38.37 | $-386.21 |
Fresh Tracks Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. The company develops sofpironium bromide, which has completed Phase III clinical trials for the treatment of primary axillary hyperhidrosis; BBI-02, an oral DYRK1A inhibitor for the treatment of autoimmune and inflammatory diseases; and BBI-10, a covalent stimulator of interferon genes inhibitor for the potential treatment of autoinflammatory and rare genetic diseases, as well as next-generation kinase inhibitors. It has license and collaboration agreements with Carna Biosciences, Inc., Voronoi Inc., Bodor Laboratories, Inc. and Dr. Nicholas S. Bodor, and AnGes, Inc. The company was formerly known as Brickell Biotech, Inc. and changed its name to Fresh Tracks Therapeutics, Inc. in September 2022. Fresh Tracks Therapeutics, Inc. was founded in 2009 and is headquartered in Boulder, Colorado.
Visit WebsiteEarnings History & Surprises
FRTXEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2025 | Mar 4, 2025 | — | — | — | — |
Q4 2024 | Dec 18, 2024 | — | — | — | — |
Q3 2024 | Sep 23, 2024 | — | — | — | — |
Q2 2024 | Jun 27, 2024 | — | — | — | — |
Q1 2024 | Mar 15, 2024 | — | $-0.20 | — | — |
Q4 2023 | Nov 13, 2023 | — | $0.32 | — | — |
Q3 2023 | Aug 11, 2023 | — | $-0.39 | — | — |
Q2 2023 | May 10, 2023 | — | $-1.14 | — | — |
Q1 2023 | Mar 30, 2023 | — | $-1.50 | — | — |
Q4 2022 | Nov 10, 2022 | $-1.89 | $-2.07 | -9.5% | ✗ MISS |
Q3 2022 | Aug 11, 2022 | $-1.44 | $-0.01 | +99.3% | ✓ BEAT |
Q2 2022 | May 12, 2022 | $-2.59 | $-3.60 | -39.0% | ✗ MISS |
Q1 2022 | Mar 15, 2022 | $-3.82 | $-2.70 | +29.3% | ✓ BEAT |
Q4 2021 | Nov 9, 2021 | $-5.62 | $-7.20 | -28.1% | ✗ MISS |
Q3 2021 | Aug 12, 2021 | $-5.62 | $-7.20 | -28.1% | ✗ MISS |
Q2 2021 | May 13, 2021 | $-5.17 | $-6.75 | -30.6% | ✗ MISS |
Q1 2021 | Mar 9, 2021 | $-4.05 | $-6.75 | -66.7% | ✗ MISS |
Q4 2020 | Nov 12, 2020 | $-8.32 | $-6.75 | +18.9% | ✓ BEAT |
Q3 2020 | Aug 12, 2020 | — | $-19.49 | — | — |
Q2 2020 | May 13, 2020 | — | $-20.28 | — | — |
Latest News
Frequently Asked Questions about FRTX
What is FRTX's current stock price?
What is the analyst price target for FRTX?
What sector is Fresh Tracks Therapeutics, Inc. in?
What is FRTX's market cap?
Does FRTX pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to FRTX for comparison